Syros Pharmaceuticals faces Nasdaq delisting risk
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Syros Pharmaceuticals Inc (SYRS)
Syros Pharmaceuticals Inc stock price live, this page displays NASDAQ SYRS stock exchange data. View the SYRS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Syros Pharmaceuticals Inc real time stock price chart below.
What Is the Syros Pharmaceuticals Inc Stock Price Today?
The Syros Pharmaceuticals Inc stock price today is 0.238.
What Is the Stock Symbol for Syros Pharmaceuticals Inc?
The stock symbol for Syros Pharmaceuticals Inc is "SYRS."
What Stock Exchange Does Syros Pharmaceuticals Inc Trade On?
Syros Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Syros Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Syros Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SYRS quote. (ISIN: US87184Q2066)
What Is the Syros Pharmaceuticals Inc Stock Price Today?
The Syros Pharmaceuticals Inc stock price today is 0.238.
What Is the Stock Symbol for Syros Pharmaceuticals Inc?
The stock symbol for Syros Pharmaceuticals Inc is "SYRS."
What Stock Exchange Does Syros Pharmaceuticals Inc Trade On?
Syros Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Syros Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Syros Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SYRS quote. (ISIN: US87184Q2066)
0.238
+0.026(+14.15%)
Closed
After Hours
0.243+0.005(+2.101%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.209
0.243
52 wk Range
0.183
7.960
SYRS Scorecard
Full Analysis
Quickly burning through cash
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.2090.243
52 wk Range
0.1837.960
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SYRS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Analysts Sentiment
Neutral
Price Target
1.000
Upside
+320.17%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Syros Pharmaceuticals Inc Company Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Syros Pharmaceuticals Inc SWOT Analysis
Clinical Setbacks | Explore the impact of Syros Pharmaceuticals' Phase 3 trial failures in MDS and AML, leading to a significant stock price decline and market reevaluation |
Financial Cushion | Delve into Syros' $58 million cash position, providing runway into Q3 2025 and potential for strategic pivots despite recent clinical disappointments |
Pipeline Prospects | Learn about Syros' challenges in advancing its remaining pipeline and the potential for leveraging its expertise in gene control for future developments |
Market Outlook | Analyst targets range from $4 to $12, with recent downgrades reflecting uncertainty. Explore potential catalysts that could revive investor confidence |
Syros Pharmaceuticals Inc Earnings Call Summary for Q3/2024
- SELECT-MDS-1 Phase 3 trial results for tamibarotene expected mid-November 2024, targeting 50% of newly diagnosed higher-risk MDS patients
- Q3 2024: No revenue, net loss of $6.4M (down from $40.1M in Q3 2023); cash reserves to fund operations into Q3 2025
- Preparations underway for tamibarotene commercial launch; market projected to exceed $800M by 2029
- Exploring business development opportunities for CDK7 inhibitor asset, 5609
- Company plans independent launch of tamibarotene upon NDA approval; final preparations focusing on market awareness and infrastructure
Last Updated: 02/11/2024, 12:20 am
Read Full TranscriptCompare SYRS to Peers and Sector
Metrics to compare | SYRS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSYRSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.1x | −3.2x | −0.6x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | −0.6x | 0.8x | 2.6x | |
Price / LTM Sales | 16.5x | 11.0x | 3.1x | |
Upside (Analyst Target) | 354.5% | 244.0% | 55.2% | |
Fair Value Upside | Unlock | 15.6% | 9.8% | Unlock |
Analyst Ratings
0 Buy
3 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 1.000
(+320.17% Upside)
Earnings
Latest Release
Oct 31, 2024
EPS / Forecast
-0.16 / -0.68
Revenue / Forecast
3.80M / 360.00K
People Also Watch
FAQ
What Is the Syros Pharma (SYRS) Stock Price Today?
The Syros Pharma stock price today is 0.238
What Stock Exchange Does Syros Pharma Trade On?
Syros Pharma is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Syros Pharma?
The stock symbol for Syros Pharma is "SYRS."
What Is the Syros Pharma Market Cap?
As of today, Syros Pharma market cap is 6.38M.
What is Syros Pharma Earnings Per Share?
The Syros Pharma EPS is -2.66.
What Is the Next Syros Pharma Earnings Date?
Syros Pharma will release its next earnings report on 05 Mar 2025.
From a Technical Analysis Perspective, Is SYRS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.